AbbVie is paying Cologne based DISCO Pharmaceuticals $40M upfront and up to $2.5B more in milestones to discover target pairs on tumors to create and validate AND-gated antibodies against them
As DISCO CEO Mark Manfredi describes, the idea behind AND-gating is that the antibodies only work where both targets, which are either exclusive or enriched on the tumor, are expressed - thus a precision medicine approach meant to target tumors and spare healthy tissue.









.png)
